Demand is growing for mammalian cell banking in support of the monoclonal antibody therapeutic and cell and gene therapy fields. Proper cell line development followed by GMP banking is required in order to introduce your therapeutic product candidate into clinical trials. In addition to protein/viral production levels and molecule structural attributes, regulatory considerations are needed during final clone selection prior to transitioning to GMP banking.
During this webinar, our experts will focus on mammalian cell line development and GMP banking requirements to transition your research from an R&D environment to the GMP regulated manufacturing world to take your molecule into the clinic. Some of the topics that will be discussed during this webinar include: